Saturday, 31 August 2013

Blueberries cut risk of type-2 diabetes

According to a study in the British Medical Journal, eating more fruit - particularly blueberries, apples and grapes - is linked to a reduced risk of developing type-2 diabetes. Blueberries were found to cut the risk by 26% compared with 2% for three servings of any whole fruit - but fruit juice did not appear to have the same effect.

The research looked at the diets of a very large sample of over 187,000 people in the US; but Diabetes UK said the results of the study should be treated with caution.

Researchers from the UK, US and Singapore used data from three large studies of nurses and health professionals in the US to examine the link between fruit consumption and the risk of contracting type-2 diabetes. In these studies, 6.5% of participants (12,198 out of 187,382) developed type-2 diabetes. The studies used food frequency questionnaires to follow up the participants every four years, asking how often, on average, they ate a standard portion of each fruit. The types of fruit used in the study were grapes or raisins, peaches, plums or apricots, prunes, bananas, cantaloupe, apples or pears, oranges, grapefruit, strawberries and blueberries.

The researchers' analysis of the data showed that three servings per week of blueberries, grapes and raisins, and apples and pears significantly reduced the risk of type-2 diabetes. While all fruit was shown to reduce the risk, these types appeared to be particularly effective. The researchers said this could be due to the fact these fruits contain high levels of anthocyanins, which have been shown to enhance glucose uptake in mice.

When they looked at the effects of fruit juice consumption, the researchers found a slightly increased risk of type-2 diabetes. It was therefore calculated that replacing weekly fruit juice consumption with whole fruits could bring health benefits. For example, replacing fruit juice with blueberries could reduce the risk of contracting type-2 diabetes by 33%, with grapes and raisins by 19%, apples and pears by 13% - and with any combination of whole fruit by 7%. Replacing fruit juice with oranges, peaches, plums and apricots had a similar effect.

Qi Sun, study author and assistant professor at Harvard School of Public Health, said, in general, fruit juices contained less of the beneficial compounds found in whole fruits. He said: "The juicing process gets rid of the fruit, just leaving fluids which are absorbed more quickly, causing blood sugars and insulin levels to rise if they contain sugars." He went on to say: "To try to minimise the risk of type-2 diabetes as much as possible it is reasonable to reduce fruit juice consumption and increase consumption of whole fruits."

Dr Matthew Hobbs, head of research for Diabetes UK, said the study provided further evidence that eating plenty of whole fruit was a key part of the balanced diet that will minimise the risk of developing type-2 diabetes. However, he said the links between type-2 diabetes and specific types of fruit or fruit drinks should be treated with caution.

Jack

Saturday, 24 August 2013

New method for building body parts

Researchers in the UK have demonstrated a way of building body parts that is similar to the way a spider spins its web. The team at University College London used a constant stream of cells mixed with a polymer to weave new tissues. The team tested the technique by constructing blood vessels in mice, and think that the technique could produce better results than other ways of building body parts for transplant.

The team at UCL are using "electrospinning" technology to produce organs. They think it will overcome some of the challenges of seeding a scaffold by building the cells into the transplant in the first place. The process starts with a broth of cells and polymer; a 10,000 volt electric needle is then used to draw out a fibre.

Dr Suwan Jayasinghe said: "Like a spider weaves its web we are able to draw out this continuous fibre of polymer and cells and weave a web. We could make one as thick as a mattress and the cells will be embedded right through it." The electrospinning technology has been used to create blood cells by cross-stitching the fibres on to a rotating cylinder which is half submerged in a liquid to nourish the living cells. Dr Jayasinghe also said: "At the moment no technology can make an organ, we are coming up with the process to patch up a defective organ not replace an organ." The idea is that a patch of heart muscle could improve function after a heart attack.

However, it is early days for the field of electrospinning. In comparison, other methods for producing body parts are already being used in patients.

Jack

Saturday, 17 August 2013

A-level results

On Thursday I picked up my A-level results from my school and was happy to learn that I'd got exactly what I needed to get into my firm choice university. 

My grades were ABB in Maths, Chemistry and Human Biology respectively as well as a B in AS Critical Thinking. This meant that I had what I needed to get into the University of Nottingham to study Biochemistry and Genetics. 

Now that's over I'm looking forward to starting there and will spend the next few weeks getting everything ready and learning all the skills I'll need to survive in my self-catered accommodation. 

Jack

Bacteria in mouth may trigger bowel cancer

Researchers say they have uncovered how mouth bacteria may set off a chain reaction leading to bowel cancer. Two US studies have revealed that fusobacteria, which are commonly found in the mouth, cause overactive immune responses and turn on cancer growth genes. The microbes have already been linked to colorectal cancer but it was not known whether they were directly involved in tumour growth. Experts hope that, in addition to potential new treatments, the discovery could lead to better early diagnosis and prevention.

The first study, carried out by researchers at Harvard Medical School, showed that fusobacteria were present in high numbers in adenomas - a benign bowel growth that can become cancerous over time. The same researchers also did tests in mice showing that the bacteria speeded up the formation of colorectal tumours by attracting special immune cells, which then invade and set off an inflammatory response which can lead to cancer.

The second study, carried out by researchers at Case Western Reserve University, showed that fusobacteria had a molecule on their surface which enabled them to attach to and invade human colorectal cancer cells. The molecule - FadA - then switches on cancer growth genes and stimulates inflammatory responses to promote tumour formation. The synthetic compound which blocked FadA was found to completely halt the process, raising the possibility it could one day be used as a preventative treatment. The Case Western team also confirmed that FadA levels were much higher in tissues from patients with adenomas and colorectal cancer compared with healthy individuals.

Dr Wendy Garrett, the lead author of the Harvard study, said: "Fusobacteria may provide not only a new way to group or describe colon cancers but also, more importantly, a new perspective on how to target pathways to halt tumour growth and spread." She added that in future the presence of the bacteria in a tumour may be used to guide treatment decisions. Oliver Childs of Cancer Research UK said: "Our bodies contain many hundreds of microbes, many of which are beneficial and protect us against disease. But some can cause harm and this latest research gives compelling evidence that fusobacteria contribute to the development of certain bowel cancers by helping the cancer cells to grow." He went on to say: "If larger studies confirm this work, a potential next step will be to develop tests to spot people at higher risk of bowel cancer or drugs that eradicate the effects of the bacteria."

Jack

Saturday, 10 August 2013

Malaria vaccine shows promise in trials

According to researchers in the US, a malaria vaccine has shown promising results in early stage clinical trials. They found that, when given in high doses, the vaccine protected 12 out of 15 patients from the disease. The method used by the researchers was unusual because it involved injecting live but weakened malaria-causing parasites directly into patients to trigger immunity.

Lead author Dr Robert Seder, from the Vaccine Research Center at the National Institute of Health, in Maryland, said: "We were excited and thrilled by the result, but it is important that we repeat it, extend it and do it in larger numbers."

For several decades it has been known that exposure to mosquitoes treated with radiation can protect against malaria. However, studies have shown that it takes more than 1,000 bites from the insects over time to build up a high level of immunity, meaning it would be an impractical method for widespread protection. Instead, a US biotech company called Sanaria has taken lab-grown mosquitoes, irradiated them and then extracted the malaria causing parasite (Plasmodiom falciparum). These living but weakened parasites are then counted and placed in vials, where they can then be injected into a patient's bloodstream.

To carry out the Phase-1 clinical trial, the researchers looked at a group of 57 volunteers, none of whom had had malaria before. Of these, 40 received different doses of the vaccine, while 17 did not. They were then all exposed to the malaria-carrying mosquitoes. The researchers found that for the 17 participants not given the vaccine, and those given low doses, almost all became infected with malaria. However, for the small group given the highest dosage, only three of the 15 patients became infected after exposure to malaria.

Dr Robert Seder said: "Based on the history, we knew dose was important because you need 1,000 mosquito bites to get protection - this validates that. It allows us in future studies to increase the dose and alter the schedule of the vaccine to further optimise it. The next critical questions will be whether the vaccine is durable over a long period of time and can the vaccine protect against other strains of malaria." He added that the fact that the vaccine had to be injected into the bloodstream rather than into or under the skin made delivery more difficult.

In total there are currently about 20 malaria vaccine candidates in clinical trials. The most advanced is called RTS,S/AS01, which has been developed by the pharmaceutical company GlaxoSmithKline, and is in a Phase-3 clinical trial involving 15,000 children in Africa.

Jack